The pharma model is deteriorating rapidly. The public demands lower drug prices, and insurers deny coverage for more new prescription drugs. To keep money flowing, acquisitions of smaller biotech companies have been increasing, but some biotechs are learning that developing a new drug requires a lot of capital. Why doesn’t pharma prepare for the future?